Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities (2016 - 2025)

Amphastar Pharmaceuticals has reported Other Non-Current Liabilities over the past 12 years, most recently at $30.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $30.0 million for Q4 2025, up 330.92% from a year ago — trailing twelve months through Dec 2025 was $30.0 million (up 330.92% YoY), and the annual figure for FY2025 was $30.0 million, up 330.92%.
  • Other Non-Current Liabilities for Q4 2025 was $30.0 million at Amphastar Pharmaceuticals, up from $7.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for AMPH hit a ceiling of $30.0 million in Q4 2025 and a floor of $6.1 million in Q4 2023.
  • Median Other Non-Current Liabilities over the past 5 years was $15.0 million (2021), compared with a mean of $15.3 million.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 334.57% in 2021 and later tumbled 74.27% in 2025.
  • Amphastar Pharmaceuticals' Other Non-Current Liabilities stood at $15.7 million in 2021, then crashed by 53.84% to $7.2 million in 2022, then decreased by 16.04% to $6.1 million in 2023, then rose by 14.69% to $7.0 million in 2024, then skyrocketed by 330.92% to $30.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $30.0 million (Q4 2025), $7.0 million (Q3 2025), and $27.8 million (Q2 2025) per Business Quant data.